Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
Abstract: Lung cancer, as one of the diseases with the highest incidence and mortality rates in the world, has always been a big challenge that humans are constantly striving to address. Pulmonary ...
The gut bacteria B. adolescentis eased lung scarring in a pulmonary fibrosis mouse model, showing potential as a preventive ...
Chilli, a Battersea rescue puppy, is now a certified Bio Detection Dog and is being trained to detect Pseudomonas aeruginosa ...
Police Chief Thomas McClain has worked in Willard for more than 30 years. Despite a serious health diagnosis, he is resolved ...
In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...
On October 3, 2025, a multicenter team from Shenzhen University, Xiangya Hospital of Central South University, Zhujiang Hospital of Southern Medical University, Wuxi People's Hospital Affiliated to ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies of the digestive system, with a 5-year survival rate of only approximately 13%, earning it the title of the "king of ...
Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback